With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and ...

Forbes contributors publish independent expert analyses and insights. I cover news on drugs and R&D in the pharma industry via my Well, I was mistaken in that view, as I was told by Ms. Sarah ...

GlaxoSmithKline is set to lay off a small number of R&D employees at its Stevenage, U.K., site as part of a wider rethink of its drug development operation. The layoffs come as GSK revises its R&D ...

The activist investor Elliott Management is pushing for change at the pharma giant GlaxoSmithKline. Among its suggestions, Elliott wants GSK to invest more in its internal R&D efforts.

GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US. The programme represents the largest capital spend by ...

Investing in companies that pay above average dividends has historically been a good investment strategy. Of course investors, specifically those looking for income, want more than just a current ...

Britain's life sciences sector plan receives a mixed reception from the pharmaceutical industry. While the strategy aims to boost R&D, industry leaders criticize the lack of resolution on drug pricing ...

GSK is a compelling value investment with a strong balance sheet, profitable drug line-up, and focus on vaccines. Click here to read more on GSK stock now.

GSK Senior Vice President, Global Head of Oncology, R&D Hesham Abdullah explained the company’s evolving cancer strategy in an interview during the J.P. Morgan Healthcare Conference in San ...

GSK delivered a stellar result for 1Q22, with turnover increasing 32% YOY (32% YOY constant exchange rate or CER) to £9.8 billion (10.5% vs. consensus).